Previous Close | 65.10 |
Open | 65.74 |
Bid | 54.00 x 2200 |
Ask | 82.00 x 800 |
Day's Range | 63.35 - 65.91 |
52 Week Range | 57.21 - 84.23 |
Volume | |
Avg. Volume | 837,977 |
Market Cap | 6.587B |
Beta (5Y Monthly) | 1.10 |
PE Ratio (TTM) | 35.73 |
EPS (TTM) | 1.82 |
Earnings Date | Feb 15, 2022 - Feb 21, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 77.71 |
Globus Medical's (GMED) Excelsius3D, when combined with ExcelsiusGPS, facilitates greater implant placement accuracy, lowers radiation exposure and reduces operative times.
Intraoperative 3D Imaging System Advances Robotic Navigation Spine SurgeryAUDUBON, Pa., May 18, 2022 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, announced today the first surgeries performed with the Excelsius3D™, an intelligent, intraoperative 3-in-1 imaging platform, the latest addition to Globus Medical’s Excelsius™ Ecosystem. Paul C. McAfee, MD, MBA and Mesfin A. Lemma, MD at MedStar Union Memorial Hospital, Roland Kent, MD at Northwest
According to Globus Medical (GMED), its Q1 results reflect modest revenue growth against a difficult prior-year comparison, coupled with COVID-related revenue impacts in key countries.